TICKERNERD
Menu
PRPOPRPOHealthcare · Diagnostics & Research

PRPO Stock Forecast: Precipio, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$22
−1.51% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 14 Oct 2026 — in the lower half.

Market cap
$40.4M
Ticker Nerd rank
47 / 100
Median analyst target
—
Analysts covering
1
Revenue$7.0M+24.2% y/y
Operating income−$599K
Net income−$219K
Free cash flow$528K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.4%
1M
−18.3%
YTD
−3.2%
1Y
+30.9%
From 52W high
−31.3%
From 52W low
+30.9%
$17
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRPO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Precipio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Volatility
71
Quality
70
Momentum
68
Growth
63
Accruals
61
Revisions
25
Value
24
Issuance
16

Size (83): Smaller than most of the companies we track.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRPO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRPO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30Jan 26Apr 26Jul 26Oct 26PRPO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Nov 2020Maxim GroupInitiatesBuy—
22 Nov 2019Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRPO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PRPO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Precipio, Inc. returned +30.9% against +17.5% for the S&P 500, dividends included.

PRPO vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26PRPOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRPO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Precipio, Inc. (PRPO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−97.4×

Cheaper than 99% of US stocks

Price / sales
1.5×

Cheaper than 59% of US stocks

Price / book
2.7×

Cheaper than 33% of US stocks

EV / EBITDA
−317.5×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
24.2%

Higher than 73% of US stocks

Earnings growth (YoY)
24.2%

Higher than 62% of US stocks

Gross margin
44.7%

Higher than 55% of US stocks

Operating margin
−8.5%

Higher than 25% of US stocks

Net margin
−4.5%

Higher than 24% of US stocks

Returns & dividend
Return on equity
−9.0%

Higher than 37% of US stocks

Return on assets
−4.8%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Precipio, Inc. (PRPO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Precipio, Inc. has a market value of $40.4M and an enterprise value of $41.0M.

  • Revenue in the twelve months to 30 June 2026: $27.2M. The latest quarter grew 24.2% year on year.

  • Net income over the same four quarters: −$1.2M, a −4.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $789K.

  • Shares outstanding: 1.8M.

  • Trailing P/E: −97.4×; forward P/E: 57.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Precipio, Inc. employs 61 people — $446K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

PRPO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
PRPOPrecipio, Inc.$40.4M
47
MDXHMDxHealth SA$60.3M
52
QUCYQuantum Cyber NV$86.6M
6
IMDXInsight Molecular Diagnostics, Inc.$89.7M
36
ADVBAdvanced Biomed, Inc.$8.5M
23
XGNExagen, Inc.$202.5M
65
XWELXWELL, Inc.$7.3M
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Precipio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRPO news & analysis

Precipio: Management Dreams Big, Institutions Have A Toe In

Seeking Alpha · 12 Oct 2026neutral

Precipio, a cancer-diagnostics laboratory services provider, has introduced an on-site testing model and is using distributors to reach new clients. Officers and directors hold 16.6% of shares; Vanguard established an initial position, and BlackRock increased its position in Q1 2026.

Why it matters — The item highlights Precipio’s expansion approach and reported institutional and insider ownership as context for PRPO watchers.

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Zacks Investment Research · 22 Sept 2026neutral

Zacks Investment Research published a comparison of Precipio (PRPO) and Fulgent Genetics (FLGT), examining differences in business scope, valuation, and growth drivers to assess which cancer diagnostics stock is more compelling at this time.

Why it matters — A PRPO watcher would care because the piece offers an analytical benchmark of Precipio against a peer in the cancer diagnostics space.

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Zacks Investment Research · 24 Aug 2026neutral

A Zacks Investment Research article compares Precipio and Biodesix, two cancer diagnostics companies with different approaches, examining which stock looks more compelling at this time.

Why it matters — A PRPO watcher would care because the piece directly evaluates Precipio against a peer in cancer diagnostics, offering a comparative view of the company.

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

Zacks Investment Research · 21 Aug 2026positive

Precipio reported second-quarter 2026 results showing strengthened revenue momentum, driven by higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation. The company's stock gained following the earnings announcement.

Why it matters — The report points to sustained revenue growth, record product sales, and improved profitability metrics, which indicate the company's momentum continued into its second quarter.

Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 17 Aug 2026neutral

Precipio, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the event. The transcript covers the company's quarterly results and management commentary.

Why it matters — A PRPO watcher would care because the earnings call transcript provides direct insight into the company's quarterly performance and management's outlook.

FAQ

Frequently asked questions about PRPO stock

Is PRPO stock a buy right now?

Of the 1 analysts covering Precipio, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precipio, Inc. 47 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRPO?

As at 14 Oct 2026, Precipio, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

What is the PRPO stock forecast for 2030?

No analyst covering Precipio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRPO are extrapolating price history, which says nothing about the business.

How has PRPO stock performed over the past year?

Precipio, Inc. returned +30.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Precipio, Inc. do?

Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction.

What is the latest news on PRPO?

The most recent item we track (Seeking Alpha, 12 Oct 2026): "Precipio: Management Dreams Big, Institutions Have A Toe In". Precipio, a cancer-diagnostics laboratory services provider, has introduced an on-site testing model and is using distributors to reach new clients. Officers and directors hold 16.6% of shares; Vanguard established an initial position, and BlackRock increased its position in Q1 2026.

Company

About Precipio, Inc.

Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction. The company provides specialized diagnostic services for blood cancers and develops proprietary products used by pathology laboratories, including genetic panels, cell culture media, and related assay technologies. Its business is organized around diagnostic services and diagnostic products, creating an integrated platform that supports testing, workflow efficiency, and clinical decision-making. Precipio Inc. also serves biopharma customers through biomarker testing and clinical project services. Based in New Haven, Connecticut, the company operates in the clinical diagnostics and life sciences markets, where it aims to improve the accuracy and utility of cancer testing for physicians, laboratories, and patients.

CEO Mr. Ilan Danieli · 61 employees · United States · https://www.precipiodx.com